학술논문
Treatment for central centrifugal cicatricial alopecia-Delphi consensus recommendations.
Document Type
Academic Journal
Author
Jackson T; University of Illinois College of Medicine, Peoria, Illinois.; Sow Y; Morehouse School of Medicine, Atlanta, Georgia.; Dinkins J; Meharry Medical College, Nashville, Tennessee.; Aguh C; Department of Dermatology, Johns Hopkins Medicine, Baltimore, Maryland.; Omueti Ayoade K; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.; Barbosa V; Section of Dermatology, University of Chicago Medicine, Chicago, Illinois.; Burgess C; Center for Dermatology and Dermatologic Surgery, Washington, District of Columbia.; Callender V; Callender Dermatology and Cosmetic Center, Glenn Dale, Maryland.; Cotsarelis G; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.; Grimes P; Grimes Center for Medical and Aesthetic Dermatology, Vitiligo and Pigmentation Institute of Southern California, Los Angeles, California.; Harvey V; Tidewater Physicians Multispecialty Group, Virginia Beach, Virginia; Hampton Roads Center for Dermatology, Newport News, Virginia.; Kindred C; Kindred Hair & Skin Center, Columbia, Maryland.; Lester J; Department of Dermatology, University of California San Francisco, San Francisco, California.; Lo Sicco K; The Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York.; Mayo T; Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama.; McMichael A; Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.; Oboite M; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.; Ogunleye T; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.; Olsen E; Department of Dermatology, Duke University, Durham, North Carolina.; Osei-Tutu A; Osei-Tutu Dermatology, Brooklyn, New York.; Piliang M; Department of Dermatology, Cleveland Clinic, Cleveland, Ohio.; Senna M; Lahey Hair Loss Center of Excellence and Research Unit, Burlington, Massachusetts.; Shapiro J; The Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York.; Tosti A; Department of Dermatology, University of Miami, Miami, Florida.; Frey C; Department of Dermatology, Howard University, Washington, District of Columbia.; Adotama P; The Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York.; Taylor SC; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: susan.taylor@pennmedicine.upenn.edu.
Source
Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE
Subject
Language
English
Abstract
Background: There is no established standard of care for treating central centrifugal cicatricial alopecia (CCCA), and treatment approaches vary widely.
Objective: To develop consensus statements regarding the use of various pharmacological therapies in treating adults with CCCA.
Methods: We invited 27 dermatologists with expertise in hair and scalp disorders to participate in a 3-round modified Delphi study between January and March 2023. Statements met strong consensus if 75% of respondents agreed or disagreed. Statements met moderate consensus if 55% or more but less than 75% agreed or disagreed.
Results: In round 1, 5 of 33 (15.2%) statements met strong consensus, followed by 9 of 28 (32.1%) in round 2. After the final round 3 meeting, strong consensus was reached for 20 of 70 (28.6%) overall statements. Two statements achieved moderate consensus.
Limitations: This study included only English-speaking, US-based dermatologists and did not consider nonpharmacological therapies.
Conclusion: Despite varying opinions among dermatologists, consensus was reached for several statements to help clinicians manage CCCA. We also highlight areas that lack expert consensus with the goal of advancing research and therapeutic options for CCCA.
Competing Interests: Conflicts of interest Dr Barbosa has served as a consultant or advisory board member to the following companies in the last 2 years: Eli Lilly, Pfizer, UCB, and Vichy. Dr Harvey has served as a consultant or advisory board member for Eli Lilly, Skinceuticals, Janssen, L’Oréal, Unilever, Pfizer, and Abbvie. Dr Mayo has served as an investigator or consultant for Arcutis, Acelyrin, BMS, ChemoCentryx, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pfizer, and Procter & Gamble. Dr McMichael has grants/research or consulting relationships with Concert, Procter & Gamble, Incyte, Eli Lilly, Janssen, Pfizer, Arcutis, Almirall, AbbVie, Galderma, Bristol Meyers Squibb, Sanofi-Genzyme, UCB, Revian, Johnson & Johnson, L'oreal, and Leo. Dr Piliang has relationships with Eli Lilly and Company, Pfizer Inc, and Procter & Gamble Company. Dr Tosti is consultant for DS Laboratories, Monat Global, Almirall, Tirthy Madison, Eli Lilly, P&G, Pfizer, Myovant, Bristol Myers Squibb, Ortho Dermatologics, Curallux LLC and PI for Eli Lilly, Concert. Dr Frey has served as a consultant or advisor for the following: Procter & Gamble, Sun Pharma, Galderma, CeraVe, La Roche Posay, Regeneron, Avita, and Ferndale. Dr Adotama has served as a consultant or advisory board member for Sanofi Regeneron, Janssen, Bristol-Myers, and Argenx. Dr Taylor has served as a consultant, advisory board member, and/or speaker for AbbVie, Arcutis, Armis Scientific, Avita, Beiersdorf, Biorez, Bristol-Myers Squibb, Cara Therapeutics, Dior, Eli Lilly, EPI Health, Evolus, Galderma, GloGetter, Hugel America, Incyte, Johnson & Johnson, L'Oreal USA, MedScape, MJH LifeSciences, Pfizer, Piction Health, Sanofi, Scientis US, UCB, and Vichy Laboratoires. She has received royalties from McGraw-Hill. She has served as an investigator for Allergan, Concert Pharmaceuticals/Sun Pharma, Croma-Pharma GmbH, Eli Lilly, and Pfizer. Authors Jackson, Sow, Dinkins, Drs Aguh, Ayoade, Burgess, Callender, Cotsarelis, Grimes, Kindred, Lester, Sicco, Oboite, Ogunleye, Olsen, Osei-Tutu, and Shapiro have no conflicts of interest to declare.
(Copyright © 2024. Published by Elsevier Inc.)
Objective: To develop consensus statements regarding the use of various pharmacological therapies in treating adults with CCCA.
Methods: We invited 27 dermatologists with expertise in hair and scalp disorders to participate in a 3-round modified Delphi study between January and March 2023. Statements met strong consensus if 75% of respondents agreed or disagreed. Statements met moderate consensus if 55% or more but less than 75% agreed or disagreed.
Results: In round 1, 5 of 33 (15.2%) statements met strong consensus, followed by 9 of 28 (32.1%) in round 2. After the final round 3 meeting, strong consensus was reached for 20 of 70 (28.6%) overall statements. Two statements achieved moderate consensus.
Limitations: This study included only English-speaking, US-based dermatologists and did not consider nonpharmacological therapies.
Conclusion: Despite varying opinions among dermatologists, consensus was reached for several statements to help clinicians manage CCCA. We also highlight areas that lack expert consensus with the goal of advancing research and therapeutic options for CCCA.
Competing Interests: Conflicts of interest Dr Barbosa has served as a consultant or advisory board member to the following companies in the last 2 years: Eli Lilly, Pfizer, UCB, and Vichy. Dr Harvey has served as a consultant or advisory board member for Eli Lilly, Skinceuticals, Janssen, L’Oréal, Unilever, Pfizer, and Abbvie. Dr Mayo has served as an investigator or consultant for Arcutis, Acelyrin, BMS, ChemoCentryx, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pfizer, and Procter & Gamble. Dr McMichael has grants/research or consulting relationships with Concert, Procter & Gamble, Incyte, Eli Lilly, Janssen, Pfizer, Arcutis, Almirall, AbbVie, Galderma, Bristol Meyers Squibb, Sanofi-Genzyme, UCB, Revian, Johnson & Johnson, L'oreal, and Leo. Dr Piliang has relationships with Eli Lilly and Company, Pfizer Inc, and Procter & Gamble Company. Dr Tosti is consultant for DS Laboratories, Monat Global, Almirall, Tirthy Madison, Eli Lilly, P&G, Pfizer, Myovant, Bristol Myers Squibb, Ortho Dermatologics, Curallux LLC and PI for Eli Lilly, Concert. Dr Frey has served as a consultant or advisor for the following: Procter & Gamble, Sun Pharma, Galderma, CeraVe, La Roche Posay, Regeneron, Avita, and Ferndale. Dr Adotama has served as a consultant or advisory board member for Sanofi Regeneron, Janssen, Bristol-Myers, and Argenx. Dr Taylor has served as a consultant, advisory board member, and/or speaker for AbbVie, Arcutis, Armis Scientific, Avita, Beiersdorf, Biorez, Bristol-Myers Squibb, Cara Therapeutics, Dior, Eli Lilly, EPI Health, Evolus, Galderma, GloGetter, Hugel America, Incyte, Johnson & Johnson, L'Oreal USA, MedScape, MJH LifeSciences, Pfizer, Piction Health, Sanofi, Scientis US, UCB, and Vichy Laboratoires. She has received royalties from McGraw-Hill. She has served as an investigator for Allergan, Concert Pharmaceuticals/Sun Pharma, Croma-Pharma GmbH, Eli Lilly, and Pfizer. Authors Jackson, Sow, Dinkins, Drs Aguh, Ayoade, Burgess, Callender, Cotsarelis, Grimes, Kindred, Lester, Sicco, Oboite, Ogunleye, Olsen, Osei-Tutu, and Shapiro have no conflicts of interest to declare.
(Copyright © 2024. Published by Elsevier Inc.)